Literature DB >> 28418444

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.

Fergus J Couch1,2, Hermela Shimelis1, Chunling Hu1, Steven N Hart2, Eric C Polley2, Jie Na2, Emily Hallberg2, Raymond Moore2, Abigail Thomas1, Jenna Lilyquist1, Bingjian Feng3, Rachel McFarland4, Tina Pesaran4, Robert Huether4, Holly LaDuca4, Elizabeth C Chao4,5, David E Goldgar3, Jill S Dolinsky4.   

Abstract

IMPORTANCE: Germline pathogenic variants in BRCA1 and BRCA2 predispose to an increased lifetime risk of breast cancer. However, the relevance of germline variants in other genes from multigene hereditary cancer testing panels is not well defined.
OBJECTIVE: To determine the risks of breast cancer associated with germline variants in cancer predisposition genes. DESIGN, SETTING, AND PARTICIPANTS: A study population of 65 057 patients with breast cancer receiving germline genetic testing of cancer predisposition genes with hereditary cancer multigene panels. Associations between pathogenic variants in non-BRCA1 and non-BRCA2 predisposition genes and breast cancer risk were estimated in a case-control analysis of patients with breast cancer and Exome Aggregation Consortium reference controls. The women underwent testing between March 15, 2012, and June 30, 2016. MAIN OUTCOMES AND MEASURES: Breast cancer risk conferred by pathogenic variants in non-BRCA1 and non-BRCA2 predisposition genes.
RESULTS: The mean (SD) age at diagnosis for the 65 057 women included in the analysis was 48.5 (11.1) years. The frequency of pathogenic variants in 21 panel genes identified in 41 611 consecutively tested white women with breast cancer was estimated at 10.2%. After exclusion of BRCA1, BRCA2, and syndromic breast cancer genes (CDH1, PTEN, and TP53), observed pathogenic variants in 5 of 16 genes were associated with high or moderately increased risks of breast cancer: ATM (OR, 2.78; 95% CI, 2.22-3.62), BARD1 (OR, 2.16; 95% CI, 1.31-3.63), CHEK2 (OR, 1.48; 95% CI, 1.31-1.67), PALB2 (OR, 7.46; 95% CI, 5.12-11.19), and RAD51D (OR, 3.07; 95% CI, 1.21-7.88). Conversely, variants in the BRIP1 and RAD51C ovarian cancer risk genes; the MRE11A, RAD50, and NBN MRN complex genes; the MLH1 and PMS2 mismatch repair genes; and NF1 were not associated with increased risks of breast cancer. CONCLUSIONS AND RELEVANCE: This study establishes several panel genes as high- and moderate-risk breast cancer genes and provides estimates of breast cancer risk associated with pathogenic variants in these genes among individuals qualifying for clinical genetic testing.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28418444      PMCID: PMC5599323          DOI: 10.1001/jamaoncol.2017.0424

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  24 in total

1.  Inherited Mutations in Women With Ovarian Carcinoma.

Authors:  Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

2.  Increased risk of breast cancer in women with NF1.

Authors:  Sara Aileen Madanikia; Amanda Bergner; Xiaobu Ye; Jaishri O'Neill Blakeley
Journal:  Am J Med Genet A       Date:  2012-11-19       Impact factor: 2.802

3.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.

Authors:  Douglas F Easton; Fabienne Lesueur; Brennan Decker; Kyriaki Michailidou; Jun Li; Jamie Allen; Craig Luccarini; Karen A Pooley; Mitul Shah; Manjeet K Bolla; Qin Wang; Joe Dennis; Jamil Ahmad; Ella R Thompson; Francesca Damiola; Maroulio Pertesi; Catherine Voegele; Noura Mebirouk; Nivonirina Robinot; Geoffroy Durand; Nathalie Forey; Robert N Luben; Shahana Ahmed; Kristiina Aittomäki; Hoda Anton-Culver; Volker Arndt; Caroline Baynes; Matthias W Beckman; Javier Benitez; David Van Den Berg; William J Blot; Natalia V Bogdanova; Stig E Bojesen; Hermann Brenner; Jenny Chang-Claude; Kee Seng Chia; Ji-Yeob Choi; Don M Conroy; Angela Cox; Simon S Cross; Kamila Czene; Hatef Darabi; Peter Devilee; Mikael Eriksson; Peter A Fasching; Jonine Figueroa; Henrik Flyger; Florentia Fostira; Montserrat García-Closas; Graham G Giles; Gord Glendon; Anna González-Neira; Pascal Guénel; Christopher A Haiman; Per Hall; Steven N Hart; Mikael Hartman; Maartje J Hooning; Chia-Ni Hsiung; Hidemi Ito; Anna Jakubowska; Paul A James; Esther M John; Nichola Johnson; Michael Jones; Maria Kabisch; Daehee Kang; Veli-Matti Kosma; Vessela Kristensen; Diether Lambrechts; Na Li; Annika Lindblom; Jirong Long; Artitaya Lophatananon; Jan Lubinski; Arto Mannermaa; Siranoush Manoukian; Sara Margolin; Keitaro Matsuo; Alfons Meindl; Gillian Mitchell; Kenneth Muir; Ines Nevelsteen; Ans van den Ouweland; Paolo Peterlongo; Sze Yee Phuah; Katri Pylkäs; Simone M Rowley; Suleeporn Sangrajrang; Rita K Schmutzler; Chen-Yang Shen; Xiao-Ou Shu; Melissa C Southey; Harald Surowy; Anthony Swerdlow; Soo H Teo; Rob A E M Tollenaar; Ian Tomlinson; Diana Torres; Thérèse Truong; Celine Vachon; Senno Verhoef; Michelle Wong-Brown; Wei Zheng; Ying Zheng; Heli Nevanlinna; Rodney J Scott; Irene L Andrulis; Anna H Wu; John L Hopper; Fergus J Couch; Robert Winqvist; Barbara Burwinkel; Elinor J Sawyer; Marjanka K Schmidt; Anja Rudolph; Thilo Dörk; Hiltrud Brauch; Ute Hamann; Susan L Neuhausen; Roger L Milne; Olivia Fletcher; Paul D P Pharoah; Ian G Campbell; Alison M Dunning; Florence Le Calvez-Kelm; David E Goldgar; Sean V Tavtigian; Georgia Chenevix-Trench
Journal:  J Med Genet       Date:  2016-02-26       Impact factor: 6.318

4.  Gene-panel sequencing and the prediction of breast-cancer risk.

Authors:  Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes
Journal:  N Engl J Med       Date:  2015-05-27       Impact factor: 91.245

5.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.

Authors:  Sheila Seal; Deborah Thompson; Anthony Renwick; Anna Elliott; Patrick Kelly; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Munaza Ahmed; Katarina Spanova; Bernard North; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

6.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.

Authors:  Holly LaDuca; A J Stuenkel; Jill S Dolinsky; Steven Keiles; Stephany Tandy; Tina Pesaran; Elaine Chen; Chia-Ling Gau; Erika Palmaer; Kamelia Shoaepour; Divya Shah; Virginia Speare; Stephanie Gandomi; Elizabeth Chao
Journal:  Genet Med       Date:  2014-04-24       Impact factor: 8.822

7.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.

Authors:  Lisa R Susswein; Megan L Marshall; Rachel Nusbaum; Kristen J Vogel Postula; Scott M Weissman; Lauren Yackowski; Erica M Vaccari; Jeffrey Bissonnette; Jessica K Booker; M Laura Cremona; Federica Gibellini; Patricia D Murphy; Daniel E Pineda-Alvarez; Guido D Pollevick; Zhixiong Xu; Gabi Richard; Sherri Bale; Rachel T Klein; Kathleen S Hruska; Wendy K Chung
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

8.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

9.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

Review 10.  Risk of breast cancer in Lynch syndrome: a systematic review.

Authors:  Aung Ko Win; Noralane M Lindor; Mark A Jenkins
Journal:  Breast Cancer Res       Date:  2013-03-19       Impact factor: 6.466

View more
  198 in total

1.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

Authors:  Allison W Kurian; Kevin C Ward; Nadia Howlader; Dennis Deapen; Ann S Hamilton; Angela Mariotto; Daniel Miller; Lynne S Penberthy; Steven J Katz
Journal:  J Clin Oncol       Date:  2019-04-09       Impact factor: 44.544

2.  A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.

Authors:  Lea M Starita; Muhtadi M Islam; Tapahsama Banerjee; Aleksandra I Adamovich; Justin Gullingsrud; Stanley Fields; Jay Shendure; Jeffrey D Parvin
Journal:  Am J Hum Genet       Date:  2018-09-12       Impact factor: 11.025

3.  The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests: Either Too Narrow or Too Broad.

Authors:  Madison K Kilbride; Angela R Bradbury
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

Review 4.  Update on Genetic Testing in Gynecologic Cancer.

Authors:  Susan M Domchek; Mark E Robson
Journal:  J Clin Oncol       Date:  2019-08-12       Impact factor: 44.544

5.  Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome.

Authors:  Tomoko Kaneyasu; Seiichi Mori; Hideko Yamauchi; Shozo Ohsumi; Shinji Ohno; Daisuke Aoki; Shinichi Baba; Junko Kawano; Yoshio Miki; Naomichi Matsumoto; Masao Nagasaki; Reiko Yoshida; Sadako Akashi-Tanaka; Takuji Iwase; Dai Kitagawa; Kenta Masuda; Akira Hirasawa; Masami Arai; Junko Takei; Yoshimi Ide; Osamu Gotoh; Noriko Yaguchi; Mitsuyo Nishi; Keika Kaneko; Yumi Matsuyama; Megumi Okawa; Misato Suzuki; Aya Nezu; Shiro Yokoyama; Sayuri Amino; Mayuko Inuzuka; Tetsuo Noda; Seigo Nakamura
Journal:  NPJ Breast Cancer       Date:  2020-06-12

6.  Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.

Authors:  Irene Konstanta; Florentia Fostira; Paraskevi Apostolou; Efstratios Stratikos; Despoina Kalfakakou; Andreas Pampanos; Panagoula Kollia; Christos Papadimitriou; Irene Konstantopoulou; Drakoulis Yannoukakos
Journal:  J Hum Genet       Date:  2018-08-15       Impact factor: 3.172

7.  Update on multi-gene panel testing and communication of genetic test results.

Authors:  Sonya Reid; Tuya Pal
Journal:  Breast J       Date:  2020-07-08       Impact factor: 2.431

8.  Exploring the effect of ascertainment bias on genetic studies that use clinical pedigrees.

Authors:  John Michael O Ranola; Ginger J Tsai; Brian H Shirts
Journal:  Eur J Hum Genet       Date:  2019-07-11       Impact factor: 4.246

9.  Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

Authors:  Renan Gomes; Pricila da Silva Spinola; Ayslan Castro Brant; Bruna Palma Matta; Caroline Macedo Nascimento; Silvia Maria de Aquino Paes; Cibele Rodrigues Bonvicino; Anna Claudia Evangelista Dos Santos; Miguel Angelo Martins Moreira
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

10.  Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.

Authors:  Kara N Maxwell; Brandon M Wenz; Abha Kulkarni; Bradley Wubbenhorst; Kurt D'Andrea; Benita Weathers; Noah Goodman; Joseph Vijai; Jenna Lilyquist; Steven N Hart; Thomas P Slavin; Kasmintan A Schrader; Vignesh Ravichandran; Tinu Thomas; Chunling Hu; Mark E Robson; Paolo Peterlongo; Bernardo Bonanni; James M Ford; Judy E Garber; Susan L Neuhausen; Payal D Shah; Angela R Bradbury; Angela M DeMichele; Kenneth Offit; Jeffrey N Weitzel; Fergus J Couch; Susan M Domchek; Katherine L Nathanson
Journal:  JCO Precis Oncol       Date:  2020-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.